AXIM BIOTECHNOLOGIES, INC. Cash Flow Statement
AXIM|9 years of annual SEC 10-K data (FY2011-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$1M
FY2023
Free Cash Flow
-$1M
FY2023
Capital Expenditures
$0
Cash used for long-term assets
Dividends Paid
N/A
FY2023
AXIM BIOTECHNOLOGIES, INC. used $1M in operating cash flow and negative free cash flow of $1M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -18.18 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$8.1M | -$6.2M | -$6.8M | -$4.2M | -$5.8M | -$10.1M | -$89.2K | -$14.9K | -$2.8K |
| Depreciation & Amortization | $427.0K | $426.1K | - | - | $3.4K | $1.1K | - | - | - |
| Operating Cash Flow | -$1.0M | -$2.0M | -$4.8M | -$3.1M | -$1.3M | -$1.5M | -$33.0K | $25.1K | $4.0K |
| Capital Expenditures | $0 | $8.7K | - | - | $0 | -$16.8K | - | - | - |
| Free Cash Flow | -$1.0M | -$2.1M | - | - | -$1.3M | -$1.5M | - | - | - |
| FCF Margin | -2607.7% | -23132.8% | - | - | -2750.0% | -3098.2% | - | - | - |